Highlights

  • CSL Limited (ASX:CSL) shares closed at AUD 166.480 on 19 August 2026, increasing 5.487% during the session.
  • FY26 Revenue was US$15.8 billion, while underlying Net Profit After Tax Before Amortisation (NPATA) was US$3.1 billion.
  • Statutory results included a US$2.6 billion net loss due to US$7.1 billion of impairments and restructuring charges.
  • FY27 guidance includes around 5% underlying NPAT growth with a focus on cost savings and operational improvements.
  • CSL maintained its Dividend and announced a new share buyback program.

CSL Limited (ASX:CSL) shares closed at AUD 166.480 on 19 August 2026, increasing AUD 8.659 or 5.487% compared with the previous close of AUD 157.820. The stock traded between AUD 159.250 and AUD 166.480, with a Volume of 3,879,713 shares.

The company recorded a Market Capitalisation of AUD 75.58 billion, with 478,911,979 ordinary fully paid shares on issue.

The share price movement followed CSL’s FY26 results announcement released on 18 August 2026, which provided further details on financial performance, impairments, Business restructuring and FY27 expectations. (CSL Limited)

Business Overview and Healthcare Operations

CSL is a global biotechnology company operating across three main businesses: CSL Behring, CSL Seqirus and CSL Vifor.

CSL Behring focuses on plasma-derived therapies, including immunoglobulins, albumin and treatments for immune deficiencies and bleeding disorders. CSL Seqirus operates in influenza vaccines and related products, while CSL Vifor focuses on iron deficiency and nephrology treatments.

The company’s Earnings are influenced by plasma collection volumes, Demand for specialty therapies, Vaccine market conditions, product competition and healthcare spending trends.

FY26 Financial Performance

For FY26, CSL reported revenue of US$15.8 billion, down approximately 1% on a constant currency basis. Underlying NPATA was US$3.1 billion, down 2%.

The statutory result was affected by significant non-recurring items, including US$7.1 billion in pre-tax impairments and US$799 million in restructuring charges. The company reported a statutory net loss of US$2.6 billion.

The impairments included adjustments related to CSL Vifor, the Lengnau Manufacturing Facility in Switzerland and self-amplifying messenger RNA intellectual property.

Operating cash flow remained positive at US$3.5 billion, supporting dividend payments and capital management activities.

Segment Performance

CSL Behring remained the largest contributor to group revenue, generating US$11.4 billion in FY26. Immunoglobulin revenue was US$6.2 billion, while hereditary angioedema revenue increased to US$884 million.

CSL Seqirus reported revenue of US$2.0 billion, with seasonal influenza revenue increasing 4% to US$1.6 billion.

CSL Vifor generated revenue of US$2.4 billion, increasing 3%. However, iron products revenue declined 16% to US$915 million due to increased competition.

The company expects CSL Vifor to remain under pressure in FY27 as generic competition continues affecting iron-related products.

FY27 Guidance and Cost Program

CSL expects FY27 revenue to remain broadly in line with FY26 on a constant currency basis, while underlying NPAT is expected to increase by approximately 5%.

The company expects CSL Behring to deliver mid-single-digit revenue growth, CSL Seqirus to achieve low single-digit growth and CSL Vifor revenue to decline.

A key part of the FY27 strategy is a cost reduction program targeting US$400 million in annual savings, increasing to US$550 million by FY28. CSL reported that US$176 million of savings had been achieved during FY26.

The company is also investing in operational improvements and growth initiatives across its businesses.

Dividend and Capital Management

CSL maintained its dividend, with FY26 dividends totalling US$2.92 per share, including a final dividend of US$1.62 per share.

The company completed a AUD 1 billion share buyback during FY26 and authorised a further AUD 1.1 billion buyback program for FY27.

Capital management remains focused on balancing Shareholder returns with Investment requirements and business transformation activities.

Key Areas to Monitor

Investors will monitor the execution of CSL’s cost savings program, recovery in CSL Behring performance, demand trends in vaccines and the impact of competition on CSL Vifor.

The appointment of a permanent chief executive and progress against FY27 guidance will also remain important factors.

The company’s ability to stabilise earnings following impairments and restructuring activities will determine future performance.

Risks and Challenges

CSL faces risks related to product competition, regulatory changes, healthcare policy, manufacturing costs and execution of its transformation program.

CSL Vifor continues facing pressure from generic competition, while CSL Seqirus is exposed to changes in influenza vaccine demand. The company also needs to demonstrate that cost savings can offset limited revenue growth.

Future impairments and delays in operational improvements remain potential risks.

Outlook

CSL enters FY27 with a focus on restoring earnings growth through cost reductions, operational improvements and performance recovery across its businesses. The company expects approximately 5% underlying NPAT growth while continuing investment in key healthcare platforms. Future results will depend on execution of the transformation program, segment performance and maintaining cash generation.

Conclusion

CSL’s share price movement on 19 August 2026 followed FY26 results that reflected a significant accounting reset alongside improved expectations for future earnings. While statutory results were affected by large impairments and restructuring costs, underlying earnings remained positive and the company maintained dividends and announced further capital returns. The focus now shifts to FY27 execution, cost savings delivery and recovery across key business segments.